Track Durysta price changes
Subscribe for DrugPrice updates by email. No spam, unsubscribe anytime.
Why Durysta Costs $944.00 Per Claim
Durysta (Bimatoprost (implant)) is used to treat eye diseases. According to CMS Medicare Part D spending data, the program spent $234.0M on this drug, covering 32,000 beneficiaries across 248,000 claims.
A generic version of this drug is available, which means lower-cost alternatives exist. Patients should ask their pharmacist about generic Bimatoprost (implant) or talk to their doctor about therapeutic alternatives that may cost less.
Spending on Durysta increased by +28.4% year-over-year, driven by increased utilization among Medicare beneficiaries.
Price Breakdown
Drug Details
Frequently Asked Questions
Durysta (Bimatoprost (implant)) costs an average of $944.00 per claim based on Medicare Part D data. The estimated annual cost per patient is $7,313.00. Actual out-of-pocket costs depend on your insurance plan and pharmacy.
Durysta averages $944.00 per Medicare Part D claim — roughly equivalent to a 30-day supply for most patients on standard dosing. Without insurance, expect higher cash-pay prices unless you use a discount program (GoodRx, SingleCare, manufacturer copay assistance). With Medicare or commercial insurance, your out-of-pocket cost depends on your plan's formulary tier and deductible status.
A typical 30-day supply of Durysta reflects in our Medicare Part D average of $944.00 per claim. Switching to generic Bimatoprost (implant) typically reduces cost by 80-95%. Cash-pay prices vary by pharmacy — comparison shopping (or using GoodRx coupons) often saves 20-50% off the listed price.
Most commercial insurance plans and Medicare Part D plans cover Durysta, but coverage varies by formulary tier. Insurers typically prefer generic Bimatoprost (implant) (Tier 1, lowest copay) over brand-name Durysta (Tier 2-3, higher copay). Some plans require prior authorization or step therapy. Check your plan's formulary or call the number on your insurance card to confirm.
Several options for cash-pay patients: (1) Manufacturer patient assistance programs — the manufacturer may offer copay cards or free-drug programs for income-qualified patients; (2) Discount programs like GoodRx, SingleCare, or RxSaver typically save 20-80% off the cash price; (3) Mark Cuban's Cost Plus Drugs offers transparent generic pricing if a generic is available; (4) 340B-eligible community health centers offer drugs at federally negotiated discounts. Switching to generic Bimatoprost (implant) is the single biggest cost reducer if your prescriber is open to it.
Brand-name Durysta costs more than generic Bimatoprost (implant) primarily for marketing reasons — patients can request the brand from their doctor even when a chemically identical generic exists. The active ingredient and clinical effect are the same.
Yes, a generic version of Durysta (Bimatoprost (implant)) is available. Generic medications typically cost 80-95% less than brand-name drugs. Ask your pharmacist about generic Bimatoprost (implant).
Medicare Part D spent $234.0M on Durysta, covering 32,000 beneficiaries across 248,000 claims. This makes it one of the tracked drugs in the Medicare spending dashboard.
Ask your pharmacist about generic Bimatoprost (implant), which is typically much cheaper. You can also compare prices at different pharmacies, use prescription discount programs (GoodRx, SingleCare, Cost Plus Drugs), or ask your doctor about therapeutic alternatives in the same drug class.
Reading Durysta's Medicare Pricing
Durysta averages $944.00 per Part D claim — a high-cost brand medication, well above the commodity-generic range but below the specialty/biologic tier. A price in this band usually signals an on-patent brand with no generic equivalent, or a brand that holds share through prescriber and patient preference even where a generic exists. For eye diseases, the gap between this price and a same-class alternative is where the real savings conversation tends to live.
Medicare spent $234.0M on Durysta across 248,000 claims and 32,000 beneficiaries — a mid-size line item. Drugs in this tier rarely make headlines but collectively make up the bulk of Part D spending. The interplay between the $944.00 average claim cost and the claim volume is what decides whether this drug's total trends up or down year to year.
Because a generic version of Bimatoprost (implant) is on the market, the realistic savings path for Durysta is straightforward: the generic is therapeutically equivalent and typically costs a fraction of the brand. The friction is usually prescribing habit rather than availability — patients can ask the prescriber to write for the generic, and most plans already steer to it with a lower copay tier. That single switch usually beats coupons, assistance programs, and pharmacy shopping combined.
Every figure here comes from the CMS Medicare Part D Drug Spending dashboard, which reports what the program paid — not the cash price at a retail pharmacy and not a patient's out-of-pocket cost. List prices also overstate the real economics: manufacturers pay confidential rebates to pharmacy benefit managers, so the net price plans actually pay is often well below the sticker. Treat $944.00 as a consistent Medicare-program benchmark for Durysta, useful for comparing drugs on the same basis, rather than the price any one patient will see at the counter.
Related
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims.